| | Sex/age | AML subtype | FAB classification | Karyotype | Other mutation assay(s) | Clinical course | PMID |
| | M/40 | De novo | M4eo | 46,XY,inv(16)(p13q22)[17]/46,XY,idem,t(9;22)(q34:q11)[3] | Not performed | Chemotherapy and HSCT; stable remission | 8250017 | | F/9 | De novo | M4eo | 46,XX,inv(16)(p13q22)[21]/46,XX,t(9;22)(q34;q11),inv(16)(p13q22)[8]/46,XX [10] | Not performed | Chemotherapy and HSCT; died soon after HSCT | 1728947 | | M/13 | De novo | M4 | 46,XY,inv(16)(p13.1q22)[2]/46,idem,del(7)(q22q32)[16]/46,idem,t(9;22;19)(q34;q11.2;p13.1)[2] | Not performed | Cytarabine, daunomycin, etoposide + gemtuzumab | 20513535 | | F/40 | De novo | M1 | 46,XX,inv(16)(p13q22)[4]/46,XX,t(9;22)(q34;q11),inv(16)(p13q22)[18] | Not performed | One cycle of conventional induction therapy | 11368385 | | M/63 | De novo | M4eo | At diagnosis: 46,XY,inv(16)(p13q22)[20]/46,XY,t(9;22)(q34;q11),inv(16)(p13q22)[2]
At last relapse: 46,XY,inv(16)(p13q22)[10]/46,XY,+8,t(9;22)(q34;q11),inv(16)(p13q22)[8] | Not performed | Hydroxycarbamide, daunorubicin/ cytarabine and imatinib with relapse in 3 months. Fludarabine, cytarabine, G-CSF and Idarubicine with complete remission but relapsed 10 months later | 21275954 | | F/49 | Therapy- related | M4eo | 46,XX,inv(16)(p13.1q22)[5]/46,XX,t(9;22)(q34;q11.2)[7]/46,XX[8] | Not performed | Imatinib; remission in 3 weeks | 22370710 | | M | De novo | M4eo | 46,XY,inv(16)(p13.1q22)[3]/46,idem,t(9;22)(q34;q11.2)[17] | None (NGS, multiple genes) | Fludarabine, cytarabine, G-CSF and Idarubicine + dasatinib; stable remission | 28253536 | | M/55 | De novo | M4eo | At Diagnosis: 46,XY,inv(16)(p13.1q22)[2]/46,sl,t(9;22)(q34;q11.2)[20]/46,XX[1].nuc ish(MYH11,CBFB)x3(MYH11 con CBFBx2)[190/200]/(ABL1,BCR)x3(ABL1 con BCRx2)[188/200]
13-day follow-up: 46,XY[2].nuc ish(ABL1,BCR)x3(ABL1 con BCRx2)[88/350]/(MYH11,CBFB)x3(MYH11 con CBFBx2)[95/350]
45-day follow-up: 46,XY[20]
188-day follow-up: 51,XY,+8,+9,+13,inv(16)(p13.1q22),+18,+22[19]/46,XY[1].nuc ish(MYH11,CBFB)x3(MYH11 con CBFBx2)[155/200]/(ABL1x2∼3,BCRx2∼3)[372/500] | None (NGS, multiple genes) | Gemtuzumab ozogamicin induction + Dasatinib; a first relapse diagnosed 6 months from initial diagnosis. Hospice. | Current case |
|
|
